Affiliation:
1. Kazan State Medical University
Abstract
In the EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58 studies, in patients with type 2 diabetes and established cardiovascular diseases or risk factors, a decrease in the risk of cardiovascular events and development or worsening of heart failure course without an increase in hypoglycemia incidence was revealed in those receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors compared with placebo. To date, various mechanisms of action of SGLT2 inhibitors have been described, which are considered from the standpoint of their influence on the course and prognosis of heart failure. In the EMPEROR-Reduced study in the group of patients receiving empagliflozin, a significant reduction in the risk of cardiovascular death and hospitalizations for heart failure, regardless of the type 2 diabetes presence, was revealed.
Subject
Cardiology and Cardiovascular Medicine
Reference52 articles.
1. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.
2. American Diabetes Association. Standards of Medical Care in Diabetes — 2014. Diabetes Care. 2014; 37(Supplement 1):S14-S80. doi:10.2337/dc14-S014.
3. Clinical recommendations. Type 2 diabetes mellitus in adults. (In Russ.) https://cr.minzdrav.gov.ru/recomend/290_1.
4. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov, 10th issue, Moscow 2021. (In Russ.)
5. Kannel WB, Hjortland M, Castelli WP, et al. Role diabetes in congestive heart failure: Framingham study. Am J Cardiol. 1974;34(1):29-34. doi:10.1016/0002-9149(74)90089-7.